Zachary Taxin is an Endocrinology/Metabolic physician affiliated with Beth Israel Deaconess Medical Center. OpenAlex indexes 24 publications with 531 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 Brookline Ave Fl 6
Boston, MA 022155400
Telephone
617-667-9344Provider last certified this registry record 23 Jan 2023.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insulet CorporationProgram year20241 payment
- Abbott LaboratoriesProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
76.9%Insulin Analog25.4%Lantus Solostar67%Humalog Kwikpen U-10033%Part D<11 patientsGLP-1 receptor agonist23.1%Trulicity63%Ozempic37%Part D<11 patients+ 2 more classes in this area
Hormonal (systemic)
13.8%l-Thyroxine13.8%Levothyroxine Sodium100%Part D<11 patientsGenitourinary & hormones
9.2%Estrogen9.2%Estradiol (Once Weekly)100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- MON-583 Lipoprotein-X-Associated Severe Peripheral Insulin Resistance Secondary to Biliary Sclerosis Treated with Plasmapheresis
Journal of the Endocrine Society
2025 - Consensus Considerations and Good Practice Points for Use of Continuous Glucose Monitoring Systems in Hospital Settings.
Carolina Digital Repository (University of North Carolina at Chapel Hill)
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Matcheri Keshavan, MD
Beth Israel Deaconess Medical Center
Connie Tsao, MD
Beth Israel Deaconess Medical Center
Donald Cutlip, MD
Beth Israel Deaconess Medical Center
Robert Yeh, MD
Beth Israel Deaconess Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”